The NEWDIGS Initiative at MIT welcomes Cerevel Therapeutics as a new collaborator on the LEAPS Project

Eric NormanLEAPS, News

Collaboration to enhance the capacity of disease ecosystems for regimen optimization

CAMBRIDGE, MA November 25, 2020 – Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, has joined the Massachusetts Institute of Technology Center for Biomedical Innovation’s New Drug Development Paradigms (NEWDIGS) initiative.

Cerevel Therapeutics is the latest company to join NEWDIGS’s expanding and diverse list of collaborators, which includes biopharmaceutical manufacturers, care providers, regulators, payers, health authorities, health technology assessment bodies, patient advocacy groups and other health care stakeholders. Within NEWDIGS’s unique safe haven environment, members support and engage in open, non-competitive collaboration to develop solutions for systemwide impediments to biomedical innovation and patient care.

Cerevel Therapeutics will participate in the Learning Ecosystems Accelerator for Patient-centered, Sustainable Innovation (LEAPS) project, which was launched in 2018 to fuel collective evolution toward sustainable, patient-centered health care. 

“Joining the NEWDIGS initiative at MIT is an example of Cerevel’s commitment to developing novel, patient-centric paradigms for bringing therapies to those that need them,” said Nirmal Keshava, vice president of data analytics and innovation science at Cerevel. “We believe the multi-disciplinary forum of stakeholders participating in NEWDIGS provides a unique ecosystem in which new models for drug discovery and development for neurological disorders can be developed.”

“Cerevel is an important and timely collaborator for the LEAPS project as we position ourselves to scale the concepts, platform strategies, tools and learnings beyond the initial target disease of Rheumatoid Arthritis and into other disease areas,” said Gigi Hirsch, MD, executive director of NEWDIGS. 

About Cerevel Therapeutics
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and substance use disorder. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit

The NEW Drug Development ParadIGmS (NEWDIGS) Initiative at MIT is an international “think and do tank” dedicated to delivering more value faster to patients, in ways that work for all stakeholders. NEWDIGS designs, evaluates and initiates advancements that are too complex and cross-cutting to be addressed by a single organization or market sector. Its members include global leaders from patient advocacy, payer organizations, biopharmaceutical companies, regulatory agencies, clinical care, academic research and investment firms. For more information, visit

Cerevel Contact
Rachel Eides
W2O pure 

Azrina Azhar
Operations Manager